Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Cora N. Sternberg, MD, of the San Camillo Forlanini Hospital, summarizes a session on the STAMPEDE and LATITUDE trials, as well as a third trial on docetaxel with androgen suppression for localized prostate cancer patients who relapsed after radical prostatectomy and/or radiotherapy (Abstracts LBA31, 783O, 784O).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma treatment; the ARIEL3 study on rucaparib vs placebo in recurrent ovarian carcinoma; and the ENGOT-OV16/NOVA on quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstracts 929O, LBA40, 930O).
Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients with incurable HPV-16+ cancer (Abstract 1136O).
